MA43734A - Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 - Google Patents

Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3

Info

Publication number
MA43734A
MA43734A MA043734A MA43734A MA43734A MA 43734 A MA43734 A MA 43734A MA 043734 A MA043734 A MA 043734A MA 43734 A MA43734 A MA 43734A MA 43734 A MA43734 A MA 43734A
Authority
MA
Morocco
Prior art keywords
inhibitor
hyperlipidemia
administration
methods
combination
Prior art date
Application number
MA043734A
Other languages
English (en)
Inventor
Jesper Gromada
Viktoria Gusarova
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA43734A publication Critical patent/MA43734A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MA043734A 2016-03-03 2017-03-01 Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3 MA43734A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662302907P 2016-03-03 2016-03-03

Publications (1)

Publication Number Publication Date
MA43734A true MA43734A (fr) 2018-11-28

Family

ID=58361088

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043734A MA43734A (fr) 2016-03-03 2017-03-01 Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3

Country Status (13)

Country Link
US (2) US20170253666A1 (fr)
EP (1) EP3423157A1 (fr)
JP (3) JP7541810B2 (fr)
KR (1) KR102456731B1 (fr)
CN (1) CN109069868B (fr)
AU (1) AU2017227713B2 (fr)
CA (1) CA3016764A1 (fr)
EA (1) EA201891979A1 (fr)
IL (2) IL325749A (fr)
MA (1) MA43734A (fr)
MX (1) MX2018010401A (fr)
WO (1) WO2017151783A1 (fr)
ZA (1) ZA201805403B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
MD3448426T2 (ro) * 2016-04-28 2025-09-30 Regeneron Pharma Metode de tratament al pacienților cu hipercolesterolemie familială
CN110464842B (zh) * 2018-05-11 2022-10-14 信达生物制药(苏州)有限公司 包含抗pcsk9抗体的制剂及其用途
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
US20220380425A1 (en) * 2019-07-04 2022-12-01 Cadila Healthcare Limited Angptl3 based vaccine for the treatment of liver disease
MX2023001481A (es) * 2020-08-07 2023-03-08 Regeneron Pharma Metodos para tratar pacientes con hipercolesterolemia refractaria.
WO2022187353A1 (fr) * 2021-03-05 2022-09-09 Anji Pharmaceuticals Inc. Procédés et compositions pour le traitement de la septicémie
CN117535353A (zh) * 2023-10-11 2024-02-09 首都医科大学附属北京潞河医院 一种糖尿病视网膜病变模型的建立方法及应用
CN117551204A (zh) * 2023-11-10 2024-02-13 中国药科大学 一种靶向pcsk9和angptl3的双特异性抗体及其制备方法与应用
WO2025185644A1 (fr) * 2024-03-05 2025-09-12 江苏恒瑞医药股份有限公司 Utilisation d'anticorps anti-angptl3 dans le traitement de l'hyperlipidémie et procédé

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
US20020035058A1 (en) 1996-05-15 2002-03-21 The University Of Sheffield Isopentenyl pyrophosphate isomerase (IPI) and/or prenyl transferase inhibitors
US6030831A (en) 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6172071B1 (en) 1998-07-30 2001-01-09 Hughes Institute Lipid-lowering quinazoline derivative
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
JP2002536459A (ja) 1999-02-12 2002-10-29 プレジデント アンド フェローズ オブ ハーヴァード カレッジ アテローム性動脈硬化症性病変の形成の阻害
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
NZ527408A (en) 2001-02-22 2005-04-29 Skyepharma Canada Inc Hydroxymethylglutarylcoenzyme A (HMG CoA) reductase inhibitor (or a statin) and a fibrate in a single effective oral dosage form to treat dyslipidaemia and dyslipoproteinaemia
KR20100029861A (ko) 2001-11-16 2010-03-17 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는 조성물 및 이를 사용하는 방법
AU2003298607B9 (en) 2002-10-29 2011-08-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP2005080508A (ja) 2003-09-04 2005-03-31 Sankyo Co Ltd 脂質代謝改善剤の試験方法
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
ZA200904022B (en) 2006-12-08 2010-08-25 Lexicon Pharmaceuticals Inc Monoclonal antibodies against ANGPTL3
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) * 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
EP2216016A1 (fr) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
CA2788777C (fr) 2009-02-23 2015-02-17 NanoRx, Inc. Nanoparticules de policosanol
CN101852805B (zh) 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
PE20160507A1 (es) 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
WO2011085271A2 (fr) 2010-01-08 2011-07-14 Isis Pharmaceuticals, Inc. Modulation de l'expression de l'analogue de l'angiopoïétine 3
WO2012168491A1 (fr) 2011-06-10 2012-12-13 Novartis Ag Formulations pharmaceutiques d'antagonistes de pcsk9
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
CA2839573A1 (fr) 2011-06-21 2012-12-27 Alnylam Pharmaceuticals, Inc. Compositions d'arni faisant intervenir la proteine 3 de type angiopoietine (angptl3) et leurs procedes d'utilisation
JP6176849B2 (ja) 2011-07-19 2017-08-09 中外製薬株式会社 アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US20150239970A1 (en) 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
ES2753381T3 (es) 2013-03-14 2020-04-08 Uab Research Foundation Miméticos de apolipoproteína y usos de los mismos
US10111953B2 (en) * 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
TW201534324A (zh) 2013-06-07 2015-09-16 Sanofi Sa 藉由投與ｐｃｓｋ９抑制劑抑制動脈粥狀硬化的方法
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
PL3087183T3 (pl) 2013-12-24 2021-01-11 Ionis Pharmaceuticals, Inc. Modulacja ekspresji białka angiopoetynopodobnego 3
WO2015168589A2 (fr) 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Compositions et méthodes de modulation de l'expression de l'angiopoïétine de type 3
KR20230074283A (ko) * 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
AU2015289617B2 (en) 2014-07-16 2021-04-15 Regeneron Pharmaceuticals, Inc. Methods for treating high cardiovascular risk patients with hypercholesterolemia
CA2954082A1 (fr) 2014-10-03 2016-04-07 Ngm Biopharmaceuticals, Inc. Methodes et compositions pour le traitement d'affections associees a des triglycerides eleves
TW201713690A (zh) 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
IL260931B2 (en) 2016-02-17 2024-09-01 Regeneron Pharma Methods of treating or preventing atherosclerosis by blocking ANGPTL3
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
PL3439689T3 (pl) 2016-04-08 2022-01-31 Regeneron Pharmaceuticals, Inc. Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3
MD3448426T2 (ro) 2016-04-28 2025-09-30 Regeneron Pharma Metode de tratament al pacienților cu hipercolesterolemie familială
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
MX2023001481A (es) 2020-08-07 2023-03-08 Regeneron Pharma Metodos para tratar pacientes con hipercolesterolemia refractaria.

Also Published As

Publication number Publication date
JP2019512472A (ja) 2019-05-16
JP2024059787A (ja) 2024-05-01
KR20180118181A (ko) 2018-10-30
CN109069868B (zh) 2023-06-06
JP2022078306A (ja) 2022-05-24
US20170253666A1 (en) 2017-09-07
JP7541810B2 (ja) 2024-08-29
US12281173B2 (en) 2025-04-22
AU2017227713B2 (en) 2022-12-22
EP3423157A1 (fr) 2019-01-09
US20200199253A1 (en) 2020-06-25
MX2018010401A (es) 2019-03-06
EA201891979A1 (ru) 2019-01-31
IL261420A (en) 2018-10-31
AU2017227713A1 (en) 2018-09-13
WO2017151783A1 (fr) 2017-09-08
ZA201805403B (en) 2019-08-28
KR102456731B1 (ko) 2022-10-24
CA3016764A1 (fr) 2017-09-08
CN109069868A (zh) 2018-12-21
IL325749A (en) 2026-03-01

Similar Documents

Publication Publication Date Title
FR25C1046I1 (fr) Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
MA51203A (fr) Combinaison d'un dérivé de 4-pyrimidinesulfamide avec un inhibiteur de sglt-2 pour le traitement de maladies liées à l'endothéline
EP3324973A4 (fr) Systèmes et procédés pour le traitement de l' il avec un photosensibilisateur
EP3386484A4 (fr) Compositions et procédés permettant d'administrer des agents thérapeutiques
ZA201805403B (en) Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an angptl3 inhibitor
EP3383404A4 (fr) Traitement du cancer à l'aide de 2-désoxy-2-fluoro-l-fucose en association avec un inhibiteur de point de contrôle
MA54622A (fr) Traitement d'affections malignes par lymphocytes b par un inhibiteur jak et pi3k combiné
EP2911669A4 (fr) Combinaison synergique d'inhibiteurs immunologiques pour le traitement du cancer
MD3416631T2 (ro) Agenți terapeutici pentru bolile neurodegenerative
MA44699A (fr) Association d'un antagoniste du pd-1 et d'un oligonucléotide cpg du type c pour le traitement du cancer
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
MA44234A (fr) Procédés de traitement ou de prévention de l'athérosclérose par administration d'un inhibiteur d'angptl3
EP3291765A4 (fr) Procédés d'administration d'un agent à l'oeil
EP2978450A4 (fr) Méthode d'amélioration de l'efficacité d'un vaccin à base de survivine pour le traitement du cancer
CR20160477A (es) Nanopartículas terapéuticas que comprenden un agente terapéutico, y métodos para su elaboración y uso
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
EP3302554A4 (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer
EP3370725A4 (fr) Dosage pédiatrique pour le traitement du cancer avec un inhibiteur d'ezh2
IL271212A (en) Methods for treating excess blood fat in diabetic patients by administering a pcsk9 inhibitor
EP3490548A4 (fr) Administration de promédicaments activés par l'hypoxie en combinaison à des agents immunomodulateurs pour le traitement du cancer
MA40271A (fr) Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib
EP3411399A4 (fr) Technologie de synergie anticorps-médicament permettant le traitement de maladies
EP4085053A4 (fr) Traitement du cancer avec des inhibiteurs de cdk12/13
EP4017349A4 (fr) Appareil thérapeutique